BRAF and melanoma: The cytotoxic behavior of complexes 2a–2e was evaluated against four human cell lines: lung adenocarcinoma (A549), melanoma BRAF WT (MeWo), bladder cancer (T24), and a non-malignant skin cell line (HaCaT).